Skip to main content

Table 3 Comparison of some comorbidities according to different symptoms subgroups

From: Gastrointestinal symptoms are associated with a lower risk of hospitalization and mortality and outcomes in COVID-19

 

Total (n = 42,964)

Group 1 (n = 1572)

Group 2 (n = 28,940)

Group 3 (n = 2615)

Group 4 (n = 9837)

P value

Comorbidities

      

Cancer

814(1.89)

33(2.0)

518 (1.8)

93 (3.56)

170 (1.73)

0.001

Diabetes

3482(8.10)

184(11.7)

2351 (8.12)

434(16.60)

513 (5.22)

0.001

CHD

3958(9.21)

148(9.4)

2700 (9.32)

443 (16.94)

667 (6.78)

0.001

Hypertension

3232(7.52)

184(11.7)

2003 (6.92)

554 (21.19)

491 (4.99)

0.001

COPD/Asthma

450 (1.05)

9 (0.6)

364 (1.25)

34 (1.30)

43 (0.44)

0.001

Chronic lung diseases

577(1.34)

12(0.8)

419(1.44)

60 (2.29)

86 (0.87)

0.001

Chronic kidney diseases

689(1.60)

43(0.02)

441(0.02)

81(0.03)

124(0.01)

0.001

Chronic blood diseases

234(1.34)

9(0.01)

159(0.01)

20(0.01)

46(0.001)

0.32

HIV/AIDS

46(0.001)

1(0.001)

34(0.001)

1(0.001)

10(0.001)

0.62

Neurological disorders

288(0.006)

15(0.01)

162(0.01)

38(0.01)

73(0.01)

0.001

  1. Qualitative variables were reported as frequency (%). To comparison of qualitative variables between four groups, the Chi-square test was used
  2. Group 1: Patients with Gastrointestinal symptoms; Group 2: Patients with respiratory symptoms; Group 3: Patients with both symptoms: Group 4: Patients with other symptoms
  3. CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease